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Recombinant human interleukm-5 (hIL-5) has been expressed at high levels and produced m large quantities in baculovirus infected Sf9 insect cells. 
The glycosylated protein was purified usmg immuno-affinity chromatography and gel filtration. Purified hIL-5 has been crystallized using standard 
vapour diffusion techniques with PEG as a coprecipitant. The crystals belong to the C2 space group and diffract to 2 A. 
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1. INTRODUCTION 
IL-5 is a cytokine secreted mainly by T,, cells during 
an allergic immune response [l]. It has been shown to 
be essential for both growth and differentiation of eo- 
sinophils in humans and mice. In the same context IL-5 
is responsible for eosinophilia observed in parasitaemia 
and allergic diseases such as chronic asthma. Since eo- 
sinophils are known to cause damage to bronchial tis- 
sue, it is believed that the reduced lung function in 
asthma is related to the number of infiltrated eosino- 
phils. Therefore the development of an IL-5 antagonist 
might have a therapeutic value. Knowledge of the struc- 
ture of hIL-5 and of the receptor binding site in partic- 
ular, would facilitate the design of such an antagonist. 
A detailed review of IL-5, its role in eosinophilia and 
related disease was published by Sanderson [2]. 
The IL-5 gene has been cloned by several groups 
[3-61. The hIL-5 cDNA codes for a mature polypeptide 
of 115 amino acids [7], corresponding to a calculated M, 
of 13,149. A larger apparent M, range is predominantly 
due to the heterogeneous addition of carbohydrate (O- 
and N-linked glycosylation in recombinant hIL-5 pro- 
duced by CHO cells [8]). Enzymatic removal of these 
sugar moieties leaves a fully active molecule, de- 
monstrating that glycosylation is not necessary for re- 
ceptor binding [9. lo]. 
In solution, hIL-5 forms an antiparallel homodimer 
via two disulfide bonds [8,1 l] which is essential for the 
biological activity of the protein [6,8,10,12,13]. 
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Recombinant hIL-5 can be produced in substantial 
quantities by transformed E. coli [14], S. cerevisiue 
[6,10], Sl9 cells [6,10] and CHO cells [8]. 
This paper describes the large scale production of 
recombinant hIL-5 using the baculovirus expression 
system (allowing for the attachment of native-like car- 
bohydrate structures), its purification. and crystalliza- 
tion. 
2. MATERIALS AND METHODS 
2.1. High level expremort of hIL-5 in Sp cells 
A synthetic hIL-5 gene [6] was inserted into the BanrHI site of the 
pVL941 vector using BumHI linkers and was integrated into the 
AcMNPV genome by cotransfection and in vivo homologous recom- 
bination in Sf9 cells as described [15]. Recombinant virus was selected 
by testing serial dilutions of the supernatants in the B13 cell prolifer- 
ation assay [16]. Recombinant plaques were picked after visual screen- 
ing. 
2.2. Large scale productton 
Sf9 cells were grown in spmner flasks using the low cost SF-l 
medium [17] supplemented with 1.5% (v/v) fetal calf serum and lipid- 
Pluromc F68 mixture (Sigma) according to Inlow et al. [18]. Scale up 
fermentation and production of recombinant hIL-5 were performed 
m airlift fermentors (Chemap AG, Switzerland) with 23 liter working 
volume according to Maiorella et al. [19]. After inoculation to an 
mitial titer of 2 x 10’ cells/ml, the cells were grown in the reactor (~0, 
30%. 27”C, pH 6.0-6.3) for 3-4 days to a density of 34 x 10’ cells/ml 
and Infected with the recombinant virus preparation at a multiplicity 
of infectton (moi) of 1-2. The production was terminated 34 days 
post-Infection by coolmg. The harvested volume was centrifuged and 
the culture supernatant concentrated lo- to 15-fold, usmg the Amicon 
SP20 ultrafiltration system (membrane cut off: 10 kDa) 
2.3. Preparation of the ntAb and the affin1t.v matrix 
A non-neutralizmg mAb (designated H30) was obtained by immu- 
nizing Wistar rats with purified baculovirus-derived hIL-5 emulsified 
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Fig. 1. SDS-(15%)-PAGE analysis of purified hIL-5. Panel A: hIL-5 (6 ,&lane) was separated and stained with Coomassie brilhant blue. Prior 
to analysis the sample was treated with 5 mM (lane 1: predommantly monomer), resp. 1 mM (lane _, ‘. disulfide bonds connecting the two monomers 
preserved) dithiothreitol. The M, of the standard proteins are inchcated on the left. Panel B. Western analysis after SDS-(IS%)-PAGE of hlL-5 
(1.5 fig/lane) in reducing (lane I) and non-reducmg (lane 2) conditions 
in Freund’s adJuvant (Gibco). Lymph node cells were fused with 
sp2/0-Ag14 mouse myeloma cells using PEG 5000 (Boehrmger) as 
previously described [20.21]. Specific mAbs were selected for then 
ability to bind “51-labeled hIL-5 (Iodogen. Pierce). H30 ascites was 
induced in pristan-primed nude mice after i.p. injectIon of the hybrid- 
omas. 
Most of the contaminants were removed from the ascites fluid by 
caprylic acid precipltatlon [22] and low speed centnfugation. The 
supernatant was dialysed versus PBS. passed over a Protein G-Sepha- 
rose column (Pharmacia) and eluted with 100 mM Trls-glycine pH 2.7. 
Fractions contaming the H30 mAb were pooled and brought to neu- 
tral pH. Alternatively. H30 was directly purified on Protnn G-Sepha- 
rose from conditioned hybridoma medium. 
120 mg H30 was coupled to Hydrazide AvidGel @loProbe Interna- 
tional) according to the manufacturer’s mstructlons 
2.4. Purificutwt 
The hIL-5 containing mechum was applied on the mAb column 
(0.25 ml/min). previously equilibrated with 20 mM KP, pH 6. Subse- 
quently the column was washed with the following successively used 
solutions: 20 mM KP, pH 6; 20 mM KP, pH 6, 0.05% (v/v) Triton 
X-100; 20 mM KP, pH 6.200 mM KCI, 50 mM Tris-HCI pH 7.4. The 
adsorbed material was eluted with 2 M MgCI,, the pooled peak frac- 
tions extensively dialysed against 50 mM Tris-HCl pH 7.4 and clarl- 
fied from precipitates by ultracentrlfugatlon. The protein solution was 
concentrated and further purified by gel filtration m 50 mM Tris-HC1 
pH 7.4,0.05% (w/v) NaN, at 1 ml/min on a TSK-G3000 SWG column 
(Ultropac 21.5 x 600 mm. TosoHaas). 
2.5. AnaJvtical methods 
SDS-PAGE was performed according to Laemmli [23]. IEF was 
performed on a Phastsystem (Pharmacia). 
Western blot analysis: proteins separated via SDS-PAGE were 
transferred to an Immobilon-P filter (Mllhpore). The membrane was 
incubated with polyclonal rabbit antiserum raised agamst yeast de- 
nved recombinant hIL-5. followed by an incubation with a sheep 
anti-rabbit IgG tagged with alkaline phosphatase (Seralab). 
Deglycosylation experiments were performed using N-Glycosidase 
F (Boehringer). according to the manufacturer’s instrucllons. 
hIL-5 was assayed for biological activity in the CTLLlCAl prolifer- 
ation assay (Cornells et al.. in preparation). For this purpose a hIL- 
5-dependent cell line was established by transfection of murme IL-7- 
50 
dependent CTLL-2 cell5 with the expression plasmid pCAGGS [25] 
contammg the hIL-5Ra cDNA. Selection was performed m the pres- 
ence of hIL-5. From several selected clones one, CTLLI/CAl. was 
further analyzed. The functional high affinity IL-5 receptor complex 
on the transfectant 1s composed of the transfected human a and the 
endogenous mouse p receptor chain (AIC2B). 
hIL-5 protein concentrations were determined using optical density 
measurements at 280 nm and a calculated E’, T$“” of 0.63 1, or measured 
according to Bradford [26], using a Blo-Rad kit with BSA as a stand- 
ard. 
N-terminal amino acid sequence analysis was carried out as previ- 
ously described [27]. 
Prior to crystallization. the protein was exammed in solution using 
laser light scattering techniques to determine their suitability for crys- 
tallizatlon. as described by Zulauf and D’Arcy [28]. 
The purified protein was concentrated to 5-6 mg/ml with an Ami- 
con 8MC unit using YM 10 membranes. A sparse matrix similar to 
that described by Jancarik and Kim [29] was set up at room tempera- 
ture using the hanging drop vapour diffusion method [30]. 
3. RESULTS AND DISCUSSION 
3.1. Espression, production and pztrzjicatiorz 
We have previously described the efficient expression 
of mature, biologically active hIL-5 in a number of 
eukaryotic expression systems [6]. The highest produc- 
tion, however, was obtained in Sf9 cells using a bacu- 
lovirus vector: 3.6 x lo4 U/ml culture medium 72 h post- 
infection, when assayed on CTLL/CAl cells, or 12 to 
18 ,ug hIL-S/ml assuming a specific biological activity of 
2- 3 x IO6 U/mg. 
The non-neutralizing mAb, H30 (isotype IgG2b). was 
found to facilitate the purification of large quantities of 
hIL-5 (11 10 mg/run/50 ml column bed) when coupled 
via its oxidized carbohydrate chains to Hydrazide 
AvidGel. 
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Fig. 2. Deglycosylation of recombinant hIL-5.7,ugprotein was treated 
(37°C; 21 h) with 1 U N-glycosidase F under denaturing condition. 
After enzymatic digestion. the sample was subjected to SDS-(15%)- 
PAGE analysis m the presence (lane 2) or absence (lane 4) of 2- 
mercaptoethanol and stained with Coomasste brilliant blue. As a con- 
trol non-treated hIL-5 was run (lane 1 and 3). 
Although the sample purity on silver-stained gels was 
estimated to be > 95% after immuno-affinity chroma- 
tography. further purification by gel filtration was em- 
ployed to remove high molecular weight- and immuno- 
complexes. Heterogeneity of the recombinant protein 
was observed on reducing and non-reducing SDS-PAA 
gels as well as on Western blot (Fig. 1): several bands 
were recognized well by a polyclonal rabbit antiserum, 
proving that they represent different isoforms of the 
same protein. Upon SDS-PAGE, deglycosylated hIL-5 
migrated as one single band (14.5 kDa under reducing 
and 27.5 kDa under non-reducing conditions in Fig. 2). 
which indicates that the several bands represent differ- 
ent glycosylation states. Analytical IEF gels showed 6-7 
discrete bands (data not shown) indicating a range of 
PI’S between 5.10 and 8.45. The major band corre- 
sponds to an IEP of 7.25 +_ 0.1 which is close to the 
theoretical value of 7.4 and also to the p1 of 7.2 deter- 
mined by Ingley et al. [lo] for yeast as well as for bacu- 
lovirus derived recombinant hIL-5. 
N-terminal analysis of the baculo-produced hI L-5 re- 
vealed the unique sequence Ile-Pro-Thr-Glu-Ile-, as pre- 
dicted from the cDNA sequence. 
3.2. Light scattering measurements 
Initial light scattering data with the protein solution 
(0.5-2.5 mg/ml) showed a bimodal distribution with hy- 
drodynamic radii between 22 A and 700 A. A radius of 
22 A would correspond to a hIL-5 dimer, while 700 A 
indicated that the sample still contained high molecular 
weight aggregates. These aggregates were removed by 
centrifugation in an airfuge (20 min 100,000 x g). The 
supernatant was reexamined and shown to be monodis- 
perse. We believe that the large aggregates originate 
from denatured molecules, resulting from the 2 M 
MgCl,, used to elute hIL-5 from the antibody column. 
3.3. Crystallization 
A sparse matrix screen, used for initial crystallization 
conditions, produced only one drop containing mi- 
crocrystals viz. in 25% PEG 4000, 100 mM MgCl,, 
100 mM cacodylate pH 6.5. The drop was touched with 
a tungsten needle and the next day long needle shaped 
crystals had grown. It has been possible to reproducibly 
grow larger needles, suitable for X-ray diffraction stud- 
ies using crystal seeding techniques. For macro seeding, 
small crystals were isolated and washed in 27.5% PEG 
8000, 100 mM MgCl,, 100 mM cacodylate pH 6.5 and 
placed in drops with 3 ~1 of protein and 3 ~1 of reservoir 
solution containing 25% PEG 8000, 100 mM MgCl,, 
100 mM cacodylate pH 6.5. Seeded crystals grew in size 
and also caused secondary nucleation for further crys- 
tals to grow. The crystal seeding techniques used are 
similar to those described in detail by Stura and Wilson 
[31]. Crystals reached a maximum size of up to 
0.8 mm x 0.12 mm x 0.12 mm after 2-3 weeks. They 
diffract to 2 A resolution and belong to the C2 space 
group with cell parameters a = 118.6 A, b = 24.4 A, c = 
45.5 A,/? = 109.2”. The crystals thus grew under similar 
conditions and belong to the same space group as those 
described recently for E. coli derived recombinant hIL-5 
[32,33]; however the cell parameters are different and (in 
contrast to what was found for the bacterial material) 
the asymmetric unit contains only one monomer. These 
differences can be explained by alternative packing, 
probably due to the carbohydrate moiety which is in- 
cluded upon crystallization. 
It is particularly important to establish that the crys- 
tallized protein contains a biologically active form. We 
have demonstrated this by washing a number of hIL-5 
crystals in stabilising buffer to remove soluble protein 
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Fig. 3. Comparison of purified recombinant hIL-5 before and after 
crystallizatton. The protein samples recovered from washed crystals 
(lanes 2 and 4) were separated on an SDS-( 15%)-PAA gel in reducing 
(lanes 1 and 2) as well as in non-reducing condittons (lanes 3 and 4) 
and silver stained following the method of Morrissey 1241. A solution 
of crystallized protein seems not to contain minor contaminants (c) 
which are seen m the startmg material (lanes 1 and 3; 0.75pg proteml 
lane). Bands ranging from 50 kDa to 68 kDa correspond wtth artifacts 
[34]. 
51 
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and testing the biological activity compared to a sample 
prior to crystallization. The recovered protein from the 
crystals proved to have a slightly higher specific biolog- 
ical activity than the starting material which may be 
explained by the fact that minor contaminants in the 
starting material were not included in the crystal as 
demonstrated in Fig. 3. From the same SDS-PAGE 
patterns. it can also be concluded that the different 
glycosylated hlL-5 forms were included into the crys- 
tals. 
Whilst this paper was in preparation. Milburn et al. 
[35] published the crystal structure of E. coli derived 
recombinant hIL-5. Further analysis is needed to verify 
that this structure fits with the one for glycosylated 
hIL-5. 
4. CONCLUSIONS 
With the availability of sufficient quantities of puri- 
fied, highly biologically active, glycosylated recombi- 
nant hIL-5, it has been possible to grow crystals suitable 
for X-ray diffraction studies. Complete native data sets 
have been collected and suitable heavy atom derivatives 
prepared. Resolution of this structure and of the recep- 
tor binding site in particular would facilitate the design 
of a low molecular weight antagonist as a potential 
pharmaceutical drug in preventing eosinophilia. 
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